

ABIONYX

A New Vision in Biotech

Capital Increase



With maintenance of preemptive subscription rights - June 2026



Cyrille TUPIN
Chief Executive Officer

€2.65
per new share

A discount of
23.74%
compared to the
on May 26, 2026

Please note,
you have until
June 15, 2026

to exercise your subscription
rights

The shares and subscription rights of ABIONYX Pharma are eligible, subject to certain conditions, for the PEA and PEA-PME. It is not possible to acquire subscription rights under the PEA or PEA-PME.

Full details on the offering:



<https://www.abionyx.com/fr/capital-increase>
infos@abionyx.com

Dear Sir or Madam, Dear Shareholder,

ABIONYX Pharma is today entering a new phase of its development.

For several years, we have been resolutely pursuing a bold ambition: to develop a new generation of biotherapies based on recombinant apolipoprotein A-I to address some of the most pressing medical needs of our time.

Over the years, your Company has undergone a profound transformation. Thanks to your trust, the commitment of our teams, and the support of our scientific and industrial partners, we have built a technology platform that is unique in the world, developed recognized industrial expertise, and achieved promising clinical results.

Today, ABIONYX Pharma now has:

- a proprietary biologic, CER-001;
- several regulatory designations (ODD, FDA/EMA) for rare diseases;
- strong institutional recognition, notably through the France 2030 program;
- and an ambitious clinical program in advanced phases with two selected therapeutic indications, including sepsis, the third leading cause of death worldwide.

The past year marked a significant acceleration in our trajectory.

The publication in Scientific Reports – *Nature* provided independent scientific validation by demonstrating the causal protective role of apoA-I in sepsis.

At the same time, our industrial and regulatory developments have continued successfully, strengthening our ability to prepare for the market launch of CER-001 in rare diseases.

Investor participation in this capital increase constitutes significant external validation of the scientific, clinical, and industrial quality of the project developed by the Company.

Thanks to this funding, ABIONYX Pharma believes it has the necessary resources to fully execute its development strategy through the end of 2028, in order to:

- fully fund the Phase 2b clinical trial in sepsis;
- submit the marketing authorization application for CER-001 in LCAT deficiency.

This financial visibility appears particularly crucial in the context of global uncertainty.

The transaction proposed today is specifically designed to reduce financial risk while allowing shareholders to benefit from the significant potential value creation associated with our future clinical and regulatory milestones.

The capital increase is being carried out with the maintenance of preemptive subscription rights, as we wanted our long-standing shareholders to have priority in participating in this major development milestone.

This mechanism allows you, if you so choose:

- maintain your stake in the Company's capital;
- benefit from attractive subscription terms;
- and to support ABIONYX Pharma in this new phase of growth.

We are convinced that the coming years will be decisive for our Company.

We hope to continue writing this new chapter in ABIONYX Pharma's history alongside you and sincerely thank you for your trust.

Cyrille Tupin
Chief Executive Officer

Why this transaction is attractive in the biotech sector:

- ▶ a **fully guaranteed** transaction of €18.7 million;
- ▶ additional **non-dilutive** financing of €10 to €14 million;
- ▶ financial visibility extended through **the end of 2028**;
- ▶ LCAT program funded through **marketing authorization**;
- ▶ Phase 2b Sepsis **fully funded**;
- ▶ Onboarding of the **first** international **institutional investor**.

7 Reasons to Invest

1 A fully secured

- ▶ The capital increase announced by ABIONYX Pharma is fully secured through guarantee commitments covering the entire amount of the transaction.
- ▶ This is particularly rare for a biotechnology company of this size.
- ▶ Several specialized institutional investors and long-standing investors have agreed to underwrite the offering for a total amount of €18.7 million, demonstrating their confidence in the Company's prospects.

This guarantee, along with non-dilutive financing of between €10 million and €14 million, provides strong financial visibility and will allow management to remain focused on executing its strategy.

2 The arrival of a leading institutional investor

- ▶ ABIONYX Pharma welcomes Fenja Capital, a Scandinavian investment fund specializing in life sciences.
- ▶ This marks Fenja's first investment outside of Scandinavia.
- ▶ This decision represents strong external validation of the Company's scientific, clinical, and industrial quality.
- ▶ Fenja is acting simultaneously:
 - as a lender for non-dilutive financing;
 - and as a guarantor of the capital increase and a new shareholder in the Company.

This three-pronged involvement demonstrates a particularly strong conviction in ABIONYX Pharma's potential for value creation.

3 Financial visibility through to value creation milestones

- ▶ One of the main risks in biotechnology lies in the need for regular refinancing before major clinical or regulatory results are achieved.
- ▶ The announced transaction provides ABIONYX Pharma with the necessary resources to execute its strategic roadmap through the next key stages of its development.
- ▶ The Company thus estimates that it has financial visibility through the end of 2028.

This visibility significantly reduces the financial risk typically associated with biotechnology companies.

4 A balanced strategy between rare diseases and sepsis

- ▶ ABIONYX Pharma currently offers a risk profile that is rare in the biotechnology sector.
- ▶ The Company is simultaneously pursuing the clinical development of its biopharmaceutical CER-001 for two therapeutic indications:
 - a global development program with very high blockbuster potential in sepsis, *the third leading cause of death worldwide*;
 - a rare disease strategy for LCAT deficiency.

5 Full funding for the sepsis program

- ▶ Proceeds from the transaction will **fully** fund the Phase 2b clinical trial of CER-001 in sepsis.
- ▶ Sepsis is currently:
 - the third leading cause of death worldwide;
 - several million deaths each year;
 - and no approved specific treatment.
- ▶ ABIONYX Pharma now has the necessary resources to conduct this study in Europe and the United States through to completion without relying on interim funding.

For shareholders, this means that the Company can now fully demonstrate the clinical potential of CER-001 in this major indication.

6 A clear regulatory path in LCAT deficiency

- ▶ A significant portion of the funds raised will be dedicated to the regulatory development of CER-001 for LCAT deficiency.
- ▶ The Company's objective is to submit a Marketing Authorization Application to the European Medicines Agency.
- ▶ The announced funding will enable:
 - the final validation batches;
 - regulatory activities.

This strategy offers investors exposure to an indication with a limited risk profile that is likely to generate value-milestones even before the results of the Phase 2b study in sepsis.

7 An opportunity to participate in a attractive terms

- ▶ The transaction is being carried out with the maintenance of preemptive subscription rights.
- ▶ Each existing shareholder is thus entitled to:
 - a preemptive right to subscribe to the new shares;
 - a subscription price of €2.65;
 - a significant discount relative to the ;
 - and the opportunity to maintain their ownership stake.
- ▶ The preemptive subscription right is a protective mechanism that is particularly favorable to existing shareholders.
- ▶ It allows each shareholder to choose freely:
 - to participate in the transaction;
 - to strengthen their position;
 - or to sell their subscription rights on the market.

Terms of the Offering

- ▶ The offering is being conducted at a ratio of 1 new share for every 5 existing shares.
- ▶ As such, each existing share entitles the holder to 1 subscription right (“Droit Préférentiel de Souscription” or DPS).
- ▶ Exercising 5 DPS entitles the holder to subscribe to 1 ABIONYX Pharma new share at a price of €2.65 per share.

1
ABIONYX Pharma
new share


at a unit price of
€2.65

for
5
Subscription rights

Euronext Paris Share ISIN Code: FR0012616852 - Ticker Symbol: ABN

DPS ISIN Code: FR0014018QN5 - Ticker Symbol: ABNDS

INDICATIVE TIMELINE FOR THE TRANSACTION



- ▶ **If you have not received your subscription form**, please contact your financial advisor as soon as possible or, if your shares are held in registered form, CIC, the registrar acting on behalf of ABIONYX Pharma
- ▶ **At the close of trading on June 15, 2026, any unexercised subscription rights will lose all value.** To protect your assets, you must either exercise them or sell them on the market during their trading period. Orders placed after the deadline will not be accepted. Depending on your situation, please contact your financial intermediary or CIC to find out the deadlines that apply to you.
- ▶ The sale of subscription rights is subject to social security contributions, capital gains tax on the sale of securities, and financial intermediary fees.
- ▶ Investors who purchased subscription rights on the market would have acquired rights that ultimately became void, resulting in a loss equal to the purchase price of the subscription rights.



Full details on the transaction

<https://www.abionyx.com/fr/augmentation-de-capital>

Your participation in the offering

as a shareholder of ABIONYX Pharma

1. Detachment of Preemptive Subscription Rights (PSR)

Each ABIONYX Pharma share held in your securities account on May 28, 2026, the day before the ex-dividend date, entitles you to one dividend. The ex-dividend date, May 29, 2026, will result in an automatic downward adjustment of the ABIONYX Pharma share price corresponding to the value of the detached dividend. Your portfolio remains unchanged following the ex-dividend date (May 29, 2026), now consisting of your ABIONYX Pharma shares without the dividend rights (known as ex-dividend shares) and your dividend rights.

2. Your options

YOU PARTICIPATE in the capital increase

OPTION 1

Full participation – exercise of all your subscription rights

You exercise all your subscription rights to subscribe for new shares on a non-cancellable basis at a price of €2.65 per share

■ You are guaranteed to receive the number of new shares corresponding to the number of subscription rights exercised.

You may also subscribe for additional new shares on a non-guaranteed basis, with no guarantee as to the number of new shares that will be allocated to you (a so-called “non-guaranteed” order).

OPTION 2

Partial exercise – exercising a portion of your subscription rights

You exercise a portion of your subscription rights and sell your unexercised subscription rights on the market during the subscription rights trading period. The proceeds from the sale of the subscription rights offset the capital dilution*.

YOU DO NOT PARTICIPATE in connection with the capital increase

OPTION 3

No tracking and sale of all your DPS

You sell all of your DPS on the market. The proceeds from the sale of the DPS offset the capital dilution in your estate*.

Don't forget to consider the tax implications of this sale and the fees charged by financial intermediaries.

OPTION 4

No participation in the transaction and no sale of your subscription rights

You do not participate and do not sell your DPS. The DPS expire at the end of the subscription period, resulting in their forfeiture without compensation or indemnification and leading to a loss of asset value for the shareholder.

3. Submission of your instructions

The deadline for buying or selling subscription rights is **June 11, 2026**, and the deadline for exercising your subscription rights is **June 15, 2026**.

IMPORTANT:

- ▶ Please pay close attention to the deadlines (cut-off dates and times) set by your financial intermediary: these deadlines vary from one intermediary to another.
- ▶ Please also take into account the delivery time for orders sent by mail. Only the date of receipt of the orders is taken into account.

Example for a shareholder holding 104 shares and choosing to participate in the transaction to the full extent of their rights

- ▶ 104 subscription rights held
- ▶ Exercise of 100 DPS entitling the holder to subscribe for 20 new shares at a price of €2.65 per share
- ▶ Subscription price = 2.65 x 20 = €53
- ▶ Sale of the 4 unused excess subscription rights

* In the event that the subscription rights are sold at their theoretical value

Public Disclosure and Risk Factors

Potential investors are advised to carefully consider the following risks:

- The Company's management will have broad discretion regarding the use of the proceeds from the Transaction and may allocate such proceeds in a manner that does not result in an increase in the value of your investment;
 - Shareholders who do not participate in the Offering will see their ownership interest in the Company's capital diluted as a result of the Offering and the issuance of new shares, or in the event of a subsequent capital increase intended to finance the Company's growth;
 - The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in connection with the Capital Increase;
 - Future sales of common shares by existing shareholders could put downward pressure on the market price of the common shares;
 - The raising of additional capital, including in connection with this Transaction or subsequent offerings intended to finance the Company's clinical programs or the commercialization of its drug candidates, may result in dilution for the Company's shareholders, restrict its operations, or require it to transfer rights to its product candidates;
- Following the implementation of the Bond Financing, the Company will incur significant debt obligations, subject to certain restrictive covenants, and, in the event of the Company's breach of these obligations, the Bondholders would be entitled to demand early repayment of the Bonds. There is no guarantee that the Company will have the necessary resources to repay its debt obligations in the event of early repayment or, more generally, upon maturity. The Company also draws attention to the risk factors described in Chapter 3 "Risk Factors" of the 2025 Universal Registration Document filed with the AMF under No. D.26 0099 dated March 17, 2026, available free of charge on the Company's website (<https://www.abionyx.com/fr/investisseurs/informations-reglementees>) as well as on the AMF's website (www.amf-france.org).

This document does not constitute a prospectus within the meaning of the Prospectus Regulation, nor does it constitute a public offering of securities.

Disclaimer

This document and the information it contains do not constitute an offer to sell or to buy, nor a solicitation of an offer to sell or to buy, any securities of Abionyx. This press release does not constitute an offer to sell or a solicitation of an offer to buy, and there will be no sale of common shares in any state or jurisdiction where such an offer, solicitation, or sale would be unlawful without registration or approval under the securities laws of that state or jurisdiction. No communication or information relating to the offering of the Company's securities may be distributed to the public in a jurisdiction where registration or approval is required. No steps have been taken or will be taken in a jurisdiction where such steps would be required. The offering or subscription of securities may be subject to specific legal or regulatory restrictions in certain jurisdictions. The Company disclaims any liability in the event of a violation of these restrictions by any person. With respect to the Member States of the European Economic Area (including France) (the "Member States"), no action has been taken and will not be taken to permit a public offering of securities that would require the publication of a prospectus in any of the Member States. Consequently, the Company's securities may not be offered and will not be offered in any of the Member States, except in accordance with the exemptions provided for in Article 1(4) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 (the "Prospectus Regulation"), or in other cases where the Company is not required to publish a prospectus pursuant to Article 1 of the Prospectus Regulation and/or the applicable regulations in the relevant Member State. This document constitutes a promotional communication and not a prospectus within the meaning of the Prospectus Regulation. Potential investors are advised to read the Information Memorandum before making an investment decision in order to understand the potential risks and benefits associated with the decision to invest in the relevant securities. This document does not constitute an offer to sell securities or a solicitation of an offer to buy securities in the United States or in any other jurisdiction where such an offer may be subject to restrictions. The securities referred to in this press release have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any applicable securities laws of any state or other jurisdiction in the United States and may not be offered or sold in the United States absent registration under the Securities Act, an exemption from registration, or a transaction not subject to registration under the Securities Act. The Company does not intend to register the offering in whole or in part in the United States or to make a public offering in the United States. The distribution of this document is not being made by, nor has it been approved by, an "authorized person" within the meaning of Section 21(1) of the Financial Services and Markets Act 2000 (the "FSMA"). Accordingly, this press release is addressed and intended solely to persons who (i) are located outside the United Kingdom, (ii) are investment professionals ("Investment Professionals") meeting the requirements of Section 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"), (iii) are persons meeting the requirements of Article 49(2)(a) to (d) (high-net-worth companies, unincorporated associations, etc.) of the Order, or (iv) are any other persons to whom this press release may be addressed in accordance with the law (the persons referred to in paragraphs (i), (ii), (iii), and (iv) being collectively referred to as "Authorized Persons"). This press release must not be acted upon or relied upon in the United Kingdom by persons who are not Authorized Persons. Any investment or investment activity in connection with this press release is restricted to Authorized Persons and may be undertaken only by such persons in the United Kingdom. This document may not be distributed, directly or indirectly, in the United States, Canada, Australia, or Japan.



Full details on the offering

<https://www.abionyx.com/fr/augmentation-de-capital>